Is NCT06335407 recruiting in West Haven, CT?

Yes, NCT06335407 is currently recruiting participants at its West Haven, CT location. This alcohol use disorder (aud) clinical trial is actively enrolling qualified participants.

How do I join the alcohol use disorder (aud) clinical trial in West Haven?

To join this clinical trial in West Haven, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this West Haven clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Alcohol Use Disorder (AUD) Clinical Trial in West Haven, CT

About This Alcohol Use Disorder (AUD) Study in West Haven

The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.

Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

Who Can Participate

Inclusion Criteria

Veterans and non-Veterans, ages 21 to 65;

Able to read and write in English and sign the informed consent;

Willing to comply with all study procedures and be available for the duration of the study;

ECG that demonstrates no clinically significant conduction issues or arrhythmias;

Have no clinically significant contraindications, in the judgement of the PI/study physician, for study participation (based on self-reported medical history and brief physical examination);

Have a current diagnosis of Alcohol use disorder (AUD) (mild, moderate, or severe) as determined by MINI-5;

Have a lifetime traumatic event in their lifetime that meets Criterion A for PTSD as determined by screening interview and the MINI-5;

Have a PCL-5 score \> 15 prior to starting the study medication;

Must have \> 1 heavy drinking episodes (\>4 standard drink units (SDU) for men; \>3 SDU for women) in the last 30 days (assessed by the Timeline Follow Back (TLFB));

Females of childbearing potential (not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for \> 6 months)) must be willing to use a medically acceptable and effective birth control method for 1 month before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms.

Exclusion Criteria

Current bipolar disorder or psychotic disorders as determined by MINI-5;

Current diagnosis of a substance use disorder (other than alcohol, nicotine, or marijuana) as determined by MINI-5;

Females who are pregnant, nursing, or planning to become pregnant during study participation;

Current physiological alcohol dependence requiring a higher level of care (e.g., detox) as determined by study physician conducting physical examination and CIWA score. Tolerance to alcohol will be allowed.

Recent history of complicated alcohol withdrawal, alcohol withdrawal seizures, or delirium tremens (DTs);

Score \> 4 on Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) at screening;

History of major medical illnesses including liver disease, heart disease, chronic pain or other medical conditions that the physician investigator deems contraindicated for the participant to be in the study;

Clinically significant history of cardiac disease including (a) chronic hypertension (even if adequately controlled by antihypertensive medications); (b) history of syncope or other syncopal attacks; (c) current evidence of orthostatic hypotension (defined as a decrease in systolic BP of 20 mm Hg or decrease in diastolic BP of 10mm Hg within 3 minutes); (d) resting heart rate of \<55 beats per minute; (e) systolic blood pressure \<110mmHg or diastolic BP \<70mmHg; or (f) participants with a QTC interval \>440msec (males) or \>460msec (females).

Clinically significant medical conditions including hepatic (ascites, bilirubin \>10% above the upper limit of normal \[ULN\] or liver function tests \[LFT\] \>3 × ULN);

Renal impairment as measured by BUN/Creatinine;

Currently taking the following medications: a) medications for alcoholism (e.g. naltrexone, disulfiram, topiramate, acamprosate); b) psychotropic medications that promote sedation including sedative/hypnotics, barbiturates, antihistamines, sedative antidepressants (e.g. doxepin, mirtazapine, trazodone), and triptans (e.g., sumatriptan); c) antihypertensive medications; d) alpha-2-adrenergic agonists (clonidine, guanfacine, lofexidine); or adrenergic agents prescribed for other reasons are excluded (prazosin). (Permitted Concomitant Medications: The concomitant medications allowed in the study include non-sedative antidepressants used to treat PTSD);

History of allergic reactions to dexmedetomidine or known allergy to dexmedetomidine;

Participation in a clinical trial of a pharmacological agent within 30 days prior to screening;

Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the study visit schedule or requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in West Haven?

Yes, this clinical trial (NCT06335407) has an active research site in West Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alcohol Use Disorder (AUD) Treatment Options in West Haven, CT

If you're searching for alcohol use disorder (aud) treatment options in West Haven, CT, this clinical trial (NCT06335407) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our West Haven research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced alcohol use disorder (aud) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alcohol use disorder (aud) clinical trials near you to find additional studies recruiting in your area.

Alcohol Use Disorder (AUD) Clinical Trial in West Haven, CT

Expert Care in West Haven

IRB Approved

No-Cost Care

Apply for This West Haven Location

Why Participate?

Simple Process